BioSpace News Archive

FDA Clears CorNeat EverPatch, World’s First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery

CorNeat Vision’s EverPatch, a synthetic tissue substitute, has been granted 510(k) clearance by the US Food & Drug Administration (FDA).

June 8, 2023
·
3 min read
FDA

Novaliq Announces FDA Approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1% for the Treatment of the Signs and Symptoms of Dry Eye Disease

Novaliq GmbH today announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.

June 8, 2023
·
5 min read
Justera Health Secures Two Retail Locations for Naturevan Stores

Justera Health Ltd. (CSE: VTAL) (OTCQB: SCRSF) (formerly ScreenPro Security Inc.) (“Justera” or the “Company”) is pleased to announce that the Company has secured two new bricks and mortar retail locations in Vancouver.

June 8, 2023
·
3 min read
Pharm Country

Qosina Partners with Carolina Components to Market their FlowLinX™ Line of Bioprocess Components

Qosina is happy to announce its partnership with Carolina Components Group, a leading supplier of primary and support production materials for the pharmaceutical and biotech manufacturing industries.

June 8, 2023
·
3 min read
Drug Development

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE™ in patients with Rett syndrome five to 20 years of age.

June 8, 2023
·
11 min read
EMRIS Pharma, the Recent Spin-off of Hadasit and Yissum, Launches the Development of a New Innovative topical drug for the Treatment of Skin Toxicities, Improving Treatment and Quality of Life for Cancer Patients

Hadasit, and Yissum, has spun off EMRIS Pharma in collaboration with NGT Healthcare2 VC.

June 8, 2023
·
5 min read
Hyloris has been granted EUR 1 million in non-dilutive funding from the Walloon Region

Hyloris Pharmaceuticals SA, a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, announced that the Company has been granted EUR 1 million in non-dilutive funding from the Walloon Region for the first part of the development of HY-083.

June 8, 2023
·
5 min read
Eitan Medical Completes Transition of Wearable Injectors Business

Eitan Medical is pleased to announce the successful completion of sale and transition of its wearable injectors business to LTS, a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems.

June 8, 2023
·
3 min read
Abivax Stock Included in MSCI Indexes

Abivax, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces that as of June 1 st, 2023, its stock is represented in the MSCI Indexes.

June 8, 2023
·
4 min read
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

A study put out by researchers at the University of Texas MD Anderson Cancer Center recently detailed a previously unexplained type of cell death that could open the door for novel cancer therapies.

June 8, 2023
·
11 min read